Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM.

Ataxia telangiectasia mutated (ATM) is an important signaling molecule in the DNA damage response (DDR). ATM loss of function can produce a synthetic lethal phenotype in combination with tumor-associated mutations in FA/BRCA pathway components. In this study, we took an siRNA screening strategy to identify other tumor suppressors that, when inhibited, similarly sensitized cells to ATM inhibition. In this manner, we determined that PTEN and ATM were synthetically lethal when jointly inhibited. PTEN-deficient cells exhibited elevated levels of reactive oxygen species, increased endogenous DNA damage, and constitutive ATM activation. ATM inhibition caused catastrophic DNA damage, mitotic cell cycle arrest, and apoptosis specifically in PTEN-deficient cells in comparison with wild-type cells. Antioxidants abrogated the increase in DNA damage and ATM activation in PTEN-deficient cells, suggesting a requirement for oxidative DNA damage in the mechanism of cell death. Lastly, the ATM inhibitor KU-60019 was specifically toxic to PTEN mutant cancer cells in tumor xenografts and reversible by reintroduction of wild-type PTEN. Together, our results offer a mechanistic rationale for clinical evaluation of ATM inhibitors in PTEN-deficient tumors.

[1]  M. Salto‐Tellez,et al.  Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma. , 2013, European urology.

[2]  Jennifer S. Yu,et al.  Nuclear PTEN Controls DNA Repair and Sensitivity to Genotoxic Stress , 2013, Science.

[3]  N. Curtin,et al.  Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer , 2013, Molecular Cancer Therapeutics.

[4]  Y. Shiloh,et al.  The ATM protein kinase: regulating the cellular response to genotoxic stress, and more , 2013, Nature Reviews Molecular Cell Biology.

[5]  A. Evans,et al.  PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy , 2011, Clinical Cancer Research.

[6]  J. Harper,et al.  Radiation induced DNA DSBs: Contribution from stalled replication forks? , 2010, DNA repair.

[7]  S. Burma,et al.  PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. , 2010, Cancer research.

[8]  A. Balmain,et al.  Guidelines for the welfare and use of animals in cancer research , 2010, British Journal of Cancer.

[9]  K. Valerie,et al.  Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion , 2009, Molecular Cancer Therapeutics.

[10]  Jung-Sik Kim,et al.  Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors , 2009, EMBO molecular medicine.

[11]  T. Pandita,et al.  Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair , 2009, Cell cycle.

[12]  A. Ashworth,et al.  Targeted therapy for cancer using PARP inhibitors. , 2008, Current opinion in pharmacology.

[13]  P. Zhou,et al.  PTEN deletion leads to deregulation of antioxidants and increased oxidative damage in mouse embryonic fibroblasts. , 2008, Free radical biology & medicine.

[14]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[15]  Akiko Shimamura,et al.  Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. , 2007, The Journal of clinical investigation.

[16]  P. Pandolfi,et al.  Essential Role for Nuclear PTEN in Maintaining Chromosomal Integrity , 2007, Cell.

[17]  Dimitris Kletsas,et al.  Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints , 2006, Nature.

[18]  N. Curtin,et al.  Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM , 2004, Cancer Research.

[19]  T. Waldman,et al.  PTEN Gene Targeting Reveals a Radiation-Induced Size Checkpoint in Human Cancer Cells , 2004, Cancer Research.

[20]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[21]  Yosef Shiloh,et al.  Recombinant ATM protein complements the cellular A-T phenotype , 1997, Oncogene.

[22]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[23]  Kp Suresh,et al.  Sample size estimation and power analysis for clinical research studies , 2012, Journal of human reproductive sciences.